Archives
SB 431542: Selective ALK5 Inhibitor for TGF-β Pathway Res...
SB 431542: Selective ALK5 Inhibitor for TGF-β Pathway Research
Executive Summary: SB 431542 is a potent ATP-competitive inhibitor targeting ALK5 in the TGF-β signaling pathway, with an IC50 of 94 nM (https://www.apexbt.com/sb-431542.html). It also inhibits ALK4 and ALK7, but not ALK1, ALK2, ALK3, or ALK6 (https://alk-1.com/index.php?g=Wap&m=Article&a=detail&id=15691). The compound effectively blocks Smad2 phosphorylation and nuclear translocation, disrupting downstream TGF-β signaling (https://doi.org/10.1016/j.jhep.2018.12.028). SB 431542 demonstrates anti-proliferative activity in glioma cell lines and enhances anti-tumor immunity in vivo (https://alk-1.com/index.php?g=Wap&m=Article&a=detail&id=15691). Its solubility profile (≥19.22 mg/mL in DMSO) and storage stability (<-20°C) make it suitable for standardized laboratory workflows (https://www.apexbt.com/sb-431542.html).
Biological Rationale
The transforming growth factor-β (TGF-β) pathway is a central mediator of cell proliferation, differentiation, and immune regulation. Overactive TGF-β signaling is implicated in cancer progression, fibrosis, and immune evasion. ALK5 (TGF-β type I receptor), a serine/threonine kinase, is essential for transducing TGF-β signals via phosphorylation of receptor-regulated Smads (chiefly Smad2/3). Selective inhibition of ALK5 is a validated approach to dissect TGF-β-mediated cellular mechanisms in both basic and translational research (https://alk-1.com/index.php?g=Wap&m=Article&a=detail&id=15691). SB 431542, offered by APExBIO, is the canonical small-molecule tool for this purpose due to its potency and selectivity.
Mechanism of Action of SB 431542
SB 431542 is an ATP-competitive inhibitor of ALK5. It binds to the ATP-binding pocket of the kinase domain, preventing receptor autophosphorylation and subsequent activation of Smad2/3. The compound exhibits an IC50 of 94 nM for ALK5. It also inhibits ALK4 and ALK7, though with reduced affinity, and has negligible activity (<1% inhibition at 10 μM) against ALK1, ALK2, ALK3, and ALK6. In cell-based assays, SB 431542 blocks phosphorylation and nuclear accumulation of Smad2, thereby halting transcriptional responses to TGF-β ligands (https://doi.org/10.1016/j.jhep.2018.12.028). This disruption is quantifiable via Western blot or immunofluorescence for p-Smad2.
Evidence & Benchmarks
- SB 431542 blocks TGF-β-induced Smad2 phosphorylation in human induced pluripotent stem cell (hiPSC) differentiation models (Wu et al., 2019, https://doi.org/10.1016/j.jhep.2018.12.028).
- In glioma cell lines (D54MG, U87MG, U373MG), SB 431542 inhibits proliferation by reducing thymidine incorporation without inducing apoptosis (APExBIO, https://www.apexbt.com/sb-431542.html).
- Intraperitoneal injection of SB 431542 enhances cytotoxic T lymphocyte activity and anti-tumor immunity in animal models, likely via modulation of dendritic cell function (APExBIO, https://alk-1.com/index.php?g=Wap&m=Article&a=detail&id=15691).
- SB 431542 is highly soluble in DMSO (≥19.22 mg/mL) and ethanol (≥10.06 mg/mL with ultrasonic treatment), but insoluble in water (APExBIO, https://www.apexbt.com/sb-431542.html).
- Stock solutions remain stable for several months below -20°C, but long-term storage of working solutions is not recommended (APExBIO, https://www.apexbt.com/sb-431542.html).
This article extends prior reviews (e.g., https://alk-1.com/index.php?g=Wap&m=Article&a=detail&id=15696) by providing updated solubility benchmarks and highlighting new translational immunology findings not previously addressed.
Applications, Limits & Misconceptions
SB 431542 is widely used in:
- Cancer research: studying TGF-β-mediated tumor cell proliferation, migration, and immune evasion (https://alk-1.com/index.php?g=Wap&m=Article&a=detail&id=15691).
- Fibrosis models: attenuating TGF-β-induced extracellular matrix deposition in hepatic, renal, and pulmonary systems (https://crispr-casx.com/index.php?g=Wap&m=Article&a=detail&id=15542).
- Stem cell differentiation: controlling endodermal and mesodermal lineage specification, e.g., in hepatobiliary organoid formation (Wu et al., 2019, https://doi.org/10.1016/j.jhep.2018.12.028).
- Anti-tumor immunology: modulating dendritic cell function and cytotoxic T lymphocyte activity (APExBIO, https://alk-1.com/index.php?g=Wap&m=Article&a=detail&id=15691).
Compared to prior guidance (https://crispr-casx.com/index.php?g=Wap&m=Article&a=detail&id=15542), this article clarifies that SB 431542's selectivity profile excludes ALK1, ALK2, ALK3, and ALK6, minimizing off-target effects in most experimental systems.
Common Pitfalls or Misconceptions
- SB 431542 is not effective against all TGF-β superfamily receptors; it does not inhibit ALK1, ALK2, ALK3, or ALK6 (<1% inhibition at 10 μM).
- The compound is insoluble in water; improper solvent use may cause precipitation or loss of activity.
- It does not induce apoptosis in glioma cells at concentrations effective for proliferation blockade (https://www.apexbt.com/sb-431542.html).
- Long-term storage of diluted solutions (>1 week at 4°C) significantly decreases potency; always prepare fresh aliquots for critical assays.
- SB 431542 is for research use only; it is not approved for diagnostic or therapeutic applications.
Workflow Integration & Parameters
SB 431542 (SKU A8249) is supplied as a solid by APExBIO and should be dissolved in DMSO (≥19.22 mg/mL) or ethanol (≥10.06 mg/mL with ultrasonic treatment). For optimal solubility, apply gentle heat (37°C) and ultrasonic shaking. Stock solutions are stable for several months at temperatures below -20°C. Working solutions should be freshly prepared and used within a week. For cell-based assays, typical working concentrations range from 1–10 μM; always include vehicle controls. In animal studies, intraperitoneal dosing protocols should be referenced from primary literature (see Wu et al., 2019 for in vivo models). For troubleshooting, see the scenario-driven guide (https://tgf-b.com/index.php?g=Wap&m=Article&a=detail&id=15863), which this article updates by specifying exact solubility and storage metrics.
To purchase or learn more about validated product specifications, visit the SB 431542 A8249 product page.
Conclusion & Outlook
SB 431542 remains the benchmark ATP-competitive ALK5 inhibitor for TGF-β pathway research. Its potency, selectivity, and robust solubility profile support its ongoing use in cancer, fibrosis, immunology, and stem cell research. Ongoing studies are expanding its utility in advanced organoid systems and translational immuno-oncology. For standardized results, strict adherence to solubility, storage, and dosing parameters is essential.